supported by the National Key R&D Program(2019YFA0111001)of China.
Chimeric antigen receptor(CAR)T-cell therapy is mostly limited to hematological malignancies and has a poor effect on solid tumors.CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs su...